A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19

NCT04380961 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

212

Enrollment

INDUSTRY

Sponsor class

Conditions

Critical Confirmed Coronavirus Disease (COVID)-19

Interventions

DRUG: Sirukumab
DRUG: Placebo
OTHER: Standard of Care (SOC)

Sponsor

Janssen Pharmaceutica N.V., Belgium